BAP1 and renal cell carcinoma: In conclusion, our study demonstrated that BAP1 or SEDT2 mutation could lead to higher expression of FoxP3 in RCC patients, and FoxP3 could eventually stimulate RCC cells’ invasion and metastasis, which might indicate that FoxP3 could function as a potential oncogene in RCC progression.